Showing 7431-7440 of 8586 results for "".
- Aclaris Announces Pricing of Initial Public Offeringhttps://practicaldermatology.com/news/aclaris-announces-pricing-of-initial-public-offering/2458854/Aclaris Therapeutics, Inc. announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a price to the public of $11.00 per share. The shares, approved for listing on The NASDAQ Global Select Market, will be traded under the ticker symbol ACRS. All of the common
- FDA Approves Juvederm® Ultra XC for Use in Lipshttps://practicaldermatology.com/news/fda-approves-juvederm-ultra-xc-for-use-in-lips/2458860/Allergan has received FDA approval to market Juvederm® Ultra XC for injection into the lips and perioral area for lip augmentation in adults over the age of 21. It is the only dermal filler that has proven results lasting up to one year for lip augmentation
- Secukinumab Phase III Data Confirm Significant Efficacy in Patients with Psoriatic Arthritishttps://practicaldermatology.com/news/secukinumab-phase-iii-data-confirm-significant-efficacy-in-patients-with-psoriatic-arthritis/2458858/Results from the Phase III FUTURE 1 study for secukinumab in psoriatic arthritis (PsA) were published online in The New England Journal of Medicine (NEJM). Secukinumab is the first interleukin-17A (IL-17A) antagonist to demonstrate efficacy in a Phase III
- Nivolumab Approved in Combination with Ipilimumabhttps://practicaldermatology.com/news/nivolumab-approved-in-combination-with-ipilimumab/2458859/The FDA has granted accelerated approval to nivolumab (Opdivo Injection, Bristol-Myers Squibb Company) in combination with ipilimumab for the treatment of patients with BRAF V600 wild-type unresectable or metastatic melanoma. The clinical trial that supported approval randomized (2:1) 142
- Curology Launches Online Service For Customized Prescription Skincarehttps://practicaldermatology.com/news/curology-launches-online-service-for-customized-prescription-skincare/2458862/Curology launched a first-of-its-kind online service that offers customized prescription creams for acne and anti-aging. Founded by dermatologist Dr. David Lortscher, Curology partners patients with licensed healthcare professionals and custom-formulates medications at its laboratory in San Diego
- Scleroderma Foundation to Honor Genentech's Dr. Jeffrey Siegel for Scientific Contributionshttps://practicaldermatology.com/news/scleroderma-foundation-to-honor-genentechs-dr-jeffrey-siegel-for-scientific-contributions/2458864/Dr. Jeffrey Siegel, Senior Group Medical Director of Immunology at Genentech, will be honored by the Scleroderma Foundation of Southern California with the Spirit of Leadership Award at their 17th annual “Key to a Cure” gala, which will be held on Saturday, Octobe
- The Osteopathic Dermatologist: Dr. Peter Ilowite Shares His Crafthttps://practicaldermatology.com/news/the-osteopathic-dermatologist-dr-peter-ilowite-shares-his-craft/2458866/Peter Ilowite, DO, Assistant Professor of Dermatology at Mt. Sinai Hospital and Dermatology Residency and an Assistant Professor of Medicine at Touro College of Osteopathic Medicine, both of New York City, spoke at the Atlantic Regional Osteopathic Convention (AROC
- 100,000 Join the ASPIRE Galderma Rewards Loyalty Program in First 90 dayshttps://practicaldermatology.com/news/100000-join-the-aspire-galderma-rewards-loyalty-program-in-the-first-90-days/2458867/Galderma’s ASPIRE Rewards program has enrolled 100,000 consumers since its launch on May 1, 2015. ASPIRE Galderma Rewards is a new loyalty program connecting US consumers and healthcare professionals using the Galderma family of aesthetic products. The vision of the Galderma a
- The National Eczema Association Names Amy Fauver New VP For Advocacy & Accesshttps://practicaldermatology.com/news/the-national-eczema-association-names-amy-fauver-new-vp-for-advocacy-access/2458872/The National Eczema Association (NEA) named Amy Fauver as Vice President for Advocacy and Access. The NEA says in this new position, Ms. Fauver will build its advocacy capacity and better leverage the voices of the eczema community, enhancing NEA’s ability to create meaningful changes in ec
- AstraZeneca and Valeant Pharmaceuticals to Partner on Brodalumabhttps://practicaldermatology.com/news/astrazeneca-and-valeant-pharmaceuticals-to-partner-on-brodalumab/2458881/AstraZeneca and Valeant Pharmaceuticals International, Inc. entered into a collaboration agreement under which AstraZeneca will grant Valeant an exclusive license to develop and commercialize brodalumab, an IL-17 receptor monoclonal antibody that is in development for patients with moderate